Search This Blog

Friday, June 12, 2020

Generation Bio prices IPO at $19

Generation Bio (GBIO) has priced its IPO of 10,526,316 common shares at $19.00/share, for expected gross proceeds of ~$200M.
Underwriters’ over-allotment is an additional 1,578,947 shares.
Trading kicks off today.
Closing date is June 16.
https://seekingalpha.com/news/3582512-generation-bio-prices-ipo-19

BeiGene antibodies show positive action on blood cancers

BeiGene (NASDAQ:BGNE) announces data from a range of ongoing studies evaluating BTK inhibitor Brukinsa (zanubrutinib) and PD-1 inhibitor tislelizumab in blood cancers. The results were virtually presented at EHA.
Phase 1/2 study of zanubrutinib in patients with B-cell malignancies: Results from the marginal zone lymphoma (MZL) cohort showed an 80% overall response rate (ORR), including a 15% complete response rate. 66.2% of responders maintained their responses at month 18. Progression-free survival (PFS) rate at month 24 was 59.4% while the rate of overall survival (OS) was 83.2%.
Four trials testing zanubrutinib in relapsed/refractory non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) showed an unadjusted average ORR of 29.8%. Median PFS was 2.8 months to 4.9 months. Median OS was 8.4 months to 11.8 months.
Phase 2 study testing combination of zanubrutinib and rituximab in relapsed/refractory non-Hodgkin lymphoma (NHL): In 20 patients with non-GCB DLBCL, the ORR was 35.0% with a median duration of response of 8.8 months. Median PKS was 3.4 months. The ORR in patients with relapsed/refractory follicular lymphoma (FL) was 56.3%. Median duration of response and median PFS was not reached. The ORR in patients with r/r MZL was 60.0%.
Phase 2 study of tislelizumab in the extranodal NK/T-cell lymphoma arm showed an ORR of 31.8% with median PFS of 2.7 months.
Phase 2 study of tislelizumab in r/r NK/T-cell neoplasms showed ORR rates of 16.7% to 23.8%. Median duration of response ranged from 3.2 months to 8.2 months.
https://seekingalpha.com/news/3582565-beigene-antibodies-show-positive-action-on-blood-cancers

Covid v. SARS: Why Quick Economic Recovery Is Unlikely

To see what economic recovery from Covid-19 could look like, some people are examining the closest modern equivalent: Hong Kong in 2003. That is when the territory’s economy was ravaged by severe acute respiratory syndrome–another epidemic caused by a coronavirus–and then staged a remarkable comeback in less than a year.
The outbreak started early in the year; by May, Hong Kong’s economy was reopening–like today. So speedy was the recovery that eight months after patients first hit hospitals, Hong Kong was hosting a $100 million concert series featuring the Rolling Stones, Prince and Neil Young.
But a closer look at SARS shows why this time a sharp recovery is unlikely–in Hong Kong or anywhere else.
Despite some similarities to Covid-19, SARS proved much easier to contain, and spread less broadly. The latest disease is more persistent and hard to detect, meaning reopenings will be slower and more tentative. And because the entire globe is infected, economies are less likely to fully revive until their trading, travel and business partners have recovered, as well.
At the depth of the SARS downturn during the second quarter of 2003, Hong Kong’s economic growth fell 2.4% from the previous quarter, before rebounding 6.1% in the third quarter. Although SARS pummeled some industries, including aviation, the impact was largely limited to Asia, and the epidemic barely registered in the global economy.
Trade, which drives Hong Kong’s economy, actually grew more than 11% in 2003 from 2002.
This time around, Hong Kong’s economic output, as measured by gross domestic product, fell 8.9% in the first quarter from the previous quarter and will likely stay negative for at least two more quarters, forecasts Singapore-based DBS Bank Ltd. Trade for the first quarter is down 10%.
Globally, economic output shrank 1.8% for the 35 major nations of the Organization for Economic Co-operation and Development in the first quarter. The OECD expects global economic activity to contract 6% this year–or 7.6% if a second wave of infections forces countries back into lockdown.
“I don’t think we will see a V-shaped recovery,” says Nicholas Kwan, research director at the Hong Kong Trade Development Council, who recalls that in 2003, everything had basically restarted by July. This time, Hong Kong has the added pressure of political unrest as China tightens its control over the population.
To get back to pre-Covid levels will take “a year or two, or even longer, ” he says.
In many ways, SARS was eerily similar to today’s crisis. The modern world’s first deadly coronavirus, it emerged in southern China, likely from a market selling wild animals to eat. Patients suffered from fever, shortness of breath and pneumonia; around 10% died.
Mr. Kwan–then a researcher at Hong Kong’s central bank–was quarantined at home for two weeks after a close friend was found to be infected. Schools closed, restaurants shut, people shunned contact with others, and everyone donned masks.
The virus spread as far afield as Canada and Vietnam. Public-health officials feared a full-fledged pandemic, and the World Health Organization advised against nonessential travel to Hong Kong and parts of China. Companies like Walmart Inc. banned employee trips to much of Asia.
Airlines based in Asia lost around $6 billion in revenue and 9% of traffic volume due to SARS–before Covid-19, the most serious blow the industry has faced from an epidemic, estimates the International Air Transport Association. Hong Kong’s visitor arrivals fell almost 68% and hotel occupancy plummeted to 18%.
But SARS ultimately proved to be much easier to contain than initially expected because it was most contagious while its victims were clearly ill–unlike Covid-19, which can be spread by people who have no idea they are infected. In all, SARS infected 8,000-plus people in more than two dozen countries before it burned out. Covid-19 has infected more than 7 million people globally.
By the summer of 2003, with the help of some social distancing and better protections for health-care workers, SARS had largely vanished.
Businesses catering to domestic demand bounced back first. Then, after the WHO lifted its travel advisory on Hong Kong in June of 2003, businesses that depended on visitors also rebounded. Subway traffic and visitor arrivals recovered in about four months; retail sales and airline traffic in around six or seven.
Hong Kong also got a huge boost from mainland China, which was booming then in a way it isn’t now, and resumed its rapid climb once the main SARS threat passed. In July of 2003, China started easing visa restrictions on individual travel to Hong Kong, which opened the floodgates to an influx of tourism that amounted to a massive stimulus.
That is not how this pandemic is playing out. In Hong Kong, as is the case everywhere, government measures to control the coronavirus have been stricter, and the corresponding economic blow much greater. Hong Kong’s retail sales fell more than 40% in February and March from a year earlier–around triple the deepest drop during SARS. Visitor arrivals in April were down 99.9%.
The entire world has thrown up barriers to travel, as the infection burns through one region after another. Most countries aren’t likely to lift those any time soon, meaning that even if domestic demand starts to recover, the sizable parts of the world’s economies that rely on travel and trade will continue to suffer. Global air traffic probably won’t recover to 2019 levels until 2023, predicts IATA.
The deeper global interconnections now than in 2003 also mean it will be hard for economies to recover until their trading and business partners do.
In Hong Kong’s Kowloon district, Danny Hussain, owner of a men’s tailor shop called La Elite Fashions, says his business won’t come back as long as the virus rages elsewhere, because he is largely dependent on business travelers and expatriates. He has laid off four of his six staff and is considering shutting shop for a few months and moving to a cheaper location if his landlord refuses to discount his rent.
It will take time for American or European customers, many of whom have lost jobs or income, to feel comfortable about traveling and splurging abroad–a problem that will play out in major cities across the globe, including Hong Kong.
“They’re not going to take a bag and travel to Hong Kong to come and buy a suit over here–first they are going to put their life back” together, says Mr. Hussain. “Things are not going to be what they used to be for some time. Those days are gone.”

https://www.marketscreener.com/news/Differences-Between-New-Coronavirus-and-SARS-Show-Why-Quick-Economic-Recovery-Is-Unlikely–30761873/

U.S. insurers use lofty estimates to beat back coronavirus claims

U.S. property and casualty insurers have cast the coronavirus pandemic as an unprecedented event whose massive cost to small businesses they are neither able nor required to cover.
The industry has warned it could cost them $255 billion to $431 billion a month if they are required, as some states are proposing, to compensate firms for income lost and expenses owed due to virus-led shutdowns, an amount it says would make insurers insolvent.
The estimate, made by the American Property Casualty Insurance Association (APCIA), a trade group, was recently used by the industry to successfully lobby against state and city lawmakers’ efforts to legislate to make the sector pay.
Insurers say business interruption policies only apply when actual physical property damage prevents a business from operating and any attempt to apply cover beyond that, for a pandemic, are unconstitutional.
The stance has discouraged some policyholders from filing claims and prompted others to take legal action.
A Reuters examination of APCIA’s estimate, however, suggests the possible bill may not be so onerous.
The APCIA estimate is an industry worst-case scenario based on all small firms with business interruption coverage being able to claim. It also assumes that between 60% and 90% of businesses with fewer than 100 employees will be impacted by COVID-19.
Only about 40% of small firms have business interruption coverage, according to the Insurance Information Institute, and most of the policies explicitly exclude pandemics, according to Tyler Leverty and Lawrence Powell, professors who specialize in insurance at the University of Wisconsin and the University of Alabama, respectively.
Powell has estimated that insurers could be on the hook for a maximum of $120 billion a month in claims on the basis that half of small firms have business interruption insurance.
Leverty said that if the estimate counted only businesses without explicit exclusions for pandemics, “it would be in the millions per month.”
The APCIA said it stood by its numbers, which it said reflect the unique and widespread impact of the virus. It declined to comment on Powell’s analysis.
“Yes, these are eye-popping figures,” APCIA Chief Executive David Sampson told Reuters, referring to the association’s estimate. “This pandemic is unprecedented in its scale, reach, and economic impact.”
NOT CLEAR-CUT
New Jersey’s business interruption bill, a model for others, is stalled while Roy Freiman, the lawmaker who introduced it, waits for an alternative plan from the industry.
“I said, ‘Look, we don’t want insolvency, but surely there is some place between 100% denial and insolvency that you can operate within,’” Freiman told Reuters.
The city council in Washington, D.C. shelved a similar plan in early May after “pretty intense” lobbying, Council Member Charles Allen, a supporter, told Reuters. APCIA’s cost estimate was cited in council discussions along with an association white paper describing the plan as unconstitutional.
Chairman Phil Mendelson, who introduced the plan, withdrew it after members voiced fears of a lengthy court fight and insurer insolvency.
“Obviously, our concerns were heard,” Sampson told Reuters at the time.
Trade groups say the industry’s stance has deterred many claims.
“Businesses are being told if you file they will probably deny you,” Andrew Wrigie, executive director of the New York City Hospitality Alliance, which represents 2,500 bars and restaurants in New York City, told Reuters.
“We’re telling them to seek counsel and be on record filing claims.”
That’s not an option for George Sizemore, owner of Bit of England Darts & Games Shoppe in Virginia Beach.
Sizemore’s insurance agent told him it would be pointless to claim for the $40,000 in revenue he said he lost while his store was shut because his policy does not cover pandemics.
“The only way I could file a claim would be to have a lawyer,” said Sizemore. “I just don’t have the money.”
There are currently dozens of lawsuits in U.S. courts seeking compensation on behalf of small businesses for lost earnings due to the pandemic.
Legal experts said that while many policies exclude pandemics, some do not and there is precedent for courts requiring insurers to pay for physical loss without physical damage, such as when pollution or asbestos make property uninhabitable.
“It’s not anywhere near as clear-cut as the industry says,” said John Ellison, a partner at Reed Smith who has represented policyholders for three decades.
https://www.marketscreener.com/news/U-S-insurers-use-lofty-estimates-to-beat-back-coronavirus-claims–30760844/?countview=0

CRISPR/Cas9 candidates show encouraging action in blood disorders

CRISPR Therapeutics (NASDAQ:CRSP) and collaboration partner Vertex Pharmaceuticals (NASDAQ:VRTX) announce new interim data from two clinical trials evaluating CRISPR/Cas9 gene-editing therapy in patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). The results were virtually presented at the European Hematology Association (EHA) Congress.
Phase 1/2 CLIMB-111 study evaluating CTX001 in TDT: Patient #1, with the  β0/IVS-I-110 genotype, required 34 units of packed red blood cells each year before enrollment. 33 days after CTX001 infusion the patient achieved neutrophil engraftment and achieved platelet engraftment in 37 days. The patient was transfusion-independent at month 15 post-treatment.
Patient #2, with the β0/IVS-II-745 genotype, required 61 units of packed red blood cells each year. After infusion with CTX001, neutrophil and platelet engraftment occurred in 36 days and 34 days, respectively. The patient remained transfusion-independent five months post-treatment.
Phase 1/2 CLIMB-121 study evaluating CTX001 in SCD: Patient #1 experienced seven vasco-occlusive crises (VOC) and five transfusions of packed red blood cells each of the prior two year before enrollment. Full neutrophil and platelet engraftment achieved in 30 days post-infusion. At month 9 patient was VOC-free and transfusion-independent.
Both studies are ongoing. Dosing being re-initiated at certain sites where the studies were temporarily paused due to COVID-19.
https://seekingalpha.com/news/3582549-crispr-cas9-candidates-show-encouraging-action-in-blood-disorders

Legal action launched against U.K. quarantine policy

British Airways (OTCPK:ICAGY), easyJet (OTCPK:EJTTF) and Ryanair (NASDAQ:RYAAY) have initiated legal action against the U.K. government’s quarantine policy, asking for a judicial review to be heard as soon as possible.
The airlines describe the rule as “flawed,” saying it will have a “devastating effect on British tourism and the wider economy.”
Instead, they want the government to reintroduce a policy from March 10, which saw passengers from countries deemed at high risk for COVID-19 being ordered to self-isolate on arrival in the U.K.
https://seekingalpha.com/news/3582524-legal-action-launched-against-u-k-quarantine-policy

Avidity Bio prices IPO at $18

Avidity Biosciences (RNA) has priced its IPO of 14.4M common shares at $18.00/share, for expected gross proceeds of $259.2M.
Underwriters’ over-allotment is an additional 2.16M shares.
Trading kicks off today.
Closing date is June 16.
https://seekingalpha.com/news/3582514-avidity-bio-prices-ipo-18